Literature DB >> 19868502

EXPERIMENTAL STUDIES OF THE NASOPHARYNGEAL SECRETIONS FROM INFLUENZA PATIENTS : II. FILTERABILITY AND RESISTANCE TO GLYCEROL.

P K Olitsky1, F L Gates.   

Abstract

All active transmissible agent present in the nasopharynx in early cases of influenza has been found to produce definite and characteristic clinical reactions and pathological effects in rabbits as already described in an earlier publication. The experiments here reported indicate that this active agent has the following properties. 1. The agent as it exists in the nasopharyngeal secretions in man, and in the lungs of rabbits injected with the human secretions, passes through Berkefeld V and N candles. 2. The filtered material produces the same effects on the circulating blood and on the lungs of rabbits as the unfiltered material. 3. The peculiar effects described as arising in the inoculated rabbit may also be induced in guinea pigs inoculated with the agent. 4. The agent responsible for the reaction on the blood and the lungs of rabbits withstands the action of glycerol in a sterile 50 per cent solution, for periods up to 9 months. The question must be left open at present whether the agent can withstand longer contact with the chemical. In two experiments after 10(1/2) months contact the agent induced no observable changes in the blood and lungs of rabbits.

Entities:  

Year:  1921        PMID: 19868502      PMCID: PMC2128189          DOI: 10.1084/jem.33.3.361

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  4 in total

1.  PRELIMINARY REPORT ON THE PRESENCE OF A "FILTER PASSING" VIRUS IN CERTAIN DISEASES: With Especial Reference to Trench Fever, Influenza, and Nephritis.

Authors:  J R Bradford; E F Bashford; J A Wilson
Journal:  Br Med J       Date:  1919-02-01

2.  THE ETIOLOGY OF INFLUENZA: A Filtrable Virus as the Cause, with some Notes on the Culture of the Virus by Noguchi's Method.

Authors:  H G Gibson; F B Bowman; J I Connor
Journal:  Br Med J       Date:  1919-03-22

3.  EXPERIMENTAL STUDIES OF THE NASOPHARYNGEAL SECRETIONS FROM INFLUENZA PATIENTS : I. TRANSMISSION EXPERIMENTS WITH NASOPHARYNGEAL WASHINGS.

Authors:  P K Olitsky; F L Gates
Journal:  J Exp Med       Date:  1921-01-31       Impact factor: 14.307

4.  NEUTRALIZATION OF THE VIRUS OF POLIOMYELITIS BY NASAL WASHINGS.

Authors:  H L Amoss; E Taylor
Journal:  J Exp Med       Date:  1917-04-01       Impact factor: 14.307

  4 in total
  8 in total

1.  Swine flu.

Authors:  Charles H Calisher
Journal:  Croat Med J       Date:  2009-08       Impact factor: 1.351

2.  EXPERIMENTAL STUDIES OF THE NASOPHARYNGEAL SECRETIONS FROM INFLUENZA PATIENTS : IX. THE RECURRENCE OF 1922.

Authors:  P K Olitsky; F L Gates
Journal:  J Exp Med       Date:  1922-10-31       Impact factor: 14.307

3.  Influenza: exposing the true killer.

Authors:  Heather L Van Epps
Journal:  J Exp Med       Date:  2006-04-17       Impact factor: 14.307

4.  AN ATTEMPT TO ISOLATE A FILTER-PASSING VIRUS IN EPIDEMIC INFLUENZA.

Authors:  H K Detweiler; W R Hodge
Journal:  J Exp Med       Date:  1924-01-01       Impact factor: 14.307

5.  EXPERIMENTAL STUDIES OF THE NASOPHARYNGEAL SECRETIONS FROM INFLUENZA PATIENTS : V. BACTERIUM PNEUMOSINTES AND CONCURRENT INFECTIONS.

Authors:  P K Olitsky; F L Gates
Journal:  J Exp Med       Date:  1921-06-30       Impact factor: 14.307

6.  EXPERIMENTAL STUDIES OF THE NASOPHARYNGEAL SECRETIONS FROM INFLUENZA PATIENTS : III. STUDIES OF THE CONCURRENT INFECTIONS.

Authors:  P K Olitsky; F L Gates
Journal:  J Exp Med       Date:  1921-02-28       Impact factor: 14.307

7.  EXPERIMENTAL STUDIES OF THE NASOPHARYNGEAL SECRETIONS FROM INFLUENZA PATIENTS : IV. ANAEROBIC CULTIVATION.

Authors:  P K Olitsky; F L Gates
Journal:  J Exp Med       Date:  1921-05-31       Impact factor: 14.307

Review 8.  The past, present and future of RNA respiratory viruses: influenza and coronaviruses.

Authors:  Vadim Makarov; Olga Riabova; Sean Ekins; Nikolay Pluzhnikov; Sergei Chepur
Journal:  Pathog Dis       Date:  2020-10-07       Impact factor: 3.166

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.